{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:03:31Z","timestamp":1794013411673,"version":"4.8.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of \u03b2-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. \u03b2-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, \u03b2-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of \u03b2-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-\u03b2-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine \u03b2-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner \u03b2-lactam activity, including in certain \u03b2-lactamase-negative strains. Preclinical\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      studies demonstrate that NAC, when combined with \u03b2-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-\u03b2-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by \u03b2-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad \u03b2-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005022","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:02:10Z","timestamp":1778266930000},"page":"3360-3369","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Nacubactam: a review on mechanistic insights and therapeutic promise for combating \u03b2-lactam resistance among multidrug-resistant Gram-negative pathogens"],"prefix":"10.1097","volume":"88","author":[{"given":"Dharmender","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Surender","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Aman","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Bibi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"R1-20260810","first-page":"e65179","article-title":"The Penicillin pioneer: Alexander Fleming\u2019s journey to a medical breakthrough","volume":"16","year":"2024","journal-title":"Cureus"},{"key":"R2-20260810","first-page":"482\u2013501","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","year":"2018","journal-title":"AIMS Microbiol"},{"key":"R3-20260810","first-page":"2474\u201381","article-title":"Management of Staphylococcus aureus infections","volume":"72","year":"2005","journal-title":"Am Fam Physician"},{"key":"R4-20260810","first-page":"3472\u2013500","article-title":"\u03b2-Lactamases and \u03b2-Lactamase Inhibitors in the 21st Century","volume":"431","year":"2019","journal-title":"J Mol Biol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ph18020206","article-title":"Breakthrough advances in beta-lactamase inhibitors: new synthesized compounds and mechanisms of action against drug-resistant bacteria","volume":"18","year":"2025","journal-title":"Pharmaceuticals"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/pathogens14020168","article-title":"\u03b2-Lactam\/\u03b2-Lactamase inhibitor combination antibiotics under development","volume":"14","year":"2025","journal-title":"Pathogens"},{"key":"R7-20260810","article-title":"Safety and pharmacokinetic characterization of nacubactam, a novel \u03b2-Lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20260810","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","year":"2025","journal-title":"Prem J Sci"},{"key":"R9-20260810","first-page":"1418\u201323","article-title":"In vitro activity and beta-lactamase stability of LJC 10,627","volume":"36","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20260810","first-page":"271\u201380","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal infections","volume":"16","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20260810","first-page":"8980\u201387","article-title":"Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 \u03b2-Lactamase","volume":"46","year":"2007","journal-title":"Biochemistry"},{"key":"R12-20260810","first-page":"545\u201348","article-title":"In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens","volume":"106","year":"2008","journal-title":"J Indian Med Assoc"},{"key":"R13-20260810","article-title":"Activity of ceftolozane\/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017\u20132019","volume":"71","year":"2022","journal-title":"J Med Microbiol"},{"key":"R14-20260810","first-page":"1684\u201392","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. Medical Centers in 2012","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"100723","DOI":"10.1016\/j.curtheres.2023.100723","article-title":"Global resistance of imipenem\/relebactam against gram-negative bacilli: systematic review and meta-analysis","volume":"100","year":"2024","journal-title":"Curr Ther Res"},{"key":"R16-20260810","article-title":"WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of gram-negative bacteria collected worldwide in 2015","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20260810","first-page":"3032\u201341","article-title":"Activity of OP0595\/\u03b2-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing \u03b2-lactamases","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260810","first-page":"2779\u201386","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R19-20260810","first-page":"S655\u2013S655","article-title":"1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with \u03b2-Lactams against \u03b2-Lactamase-Producing Enterobacterales Isolated in Japan","volume":"7","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R20-20260810","article-title":"Efficacy of human-simulated epithelial lining fluid exposure of meropenem-nacubactam combination against class a serine \u03b2-Lactamase-Producing Enterobacteriaceae in the neutropenic murine lung infection model","volume":"63","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20260810","article-title":"In Vivo efficacy of meropenem with a novel Non-\u03b2-Lactam\u2013\u03b2-Lactamase inhibitor, nacubactam, against gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20260810","doi-asserted-by":"crossref","first-page":"105838","DOI":"10.1016\/j.ijantimicag.2019.10.019","article-title":"Meropenem\u2013nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model","volume":"55","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R23-20260810","article-title":"Nacubactam enhances meropenem activity against carbapenem-resistant klebsiella pneumoniae producing KPC","volume":"63","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20260810","first-page":"953\u201360","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R25-20260810","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: a systematic review of in vitro studies and clinical cases","volume":"10","year":"2021","journal-title":"Antibiotics"},{"key":"R26-20260810","first-page":"101\u201307","article-title":"In vitro activity of aztreonam in combination with newly developed \u03b2-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-\u03b2-lactamases","volume":"78","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R27-20260810","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by Metallo-\u03b2-Lactamase-Producing Gram-Negative bacteria","volume":"63","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20260810","first-page":"S251\u20132","article-title":"698. Nacubactam Inhibits Class A \u03b2-lactamases","volume":"5","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R29-20260810","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/antibiotics10080995","article-title":"Old and New Beta-Lactamase inhibitors: molecular structure, mechanism of action, and clinical use","volume":"10","year":"2021","journal-title":"Antibiotics"},{"key":"R30-20260810","article-title":"Bicyclic boronate \u03b2-Lactamase inhibitors: the present hope against deadly bacterial pathogens","volume":"4","year":"2021","journal-title":"Adv Ther (Weinh)"},{"key":"R31-20260810","first-page":"1041\u201368","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","year":"2025","journal-title":"Eu J Clin Microbiol Infect Dis"},{"key":"R32-20260810","first-page":"5441\u201355","article-title":"Electrostatic interactions influence diazabicyclooctane inhibitor potency against OXA-48-like \u03b2-lactamases","volume":"16","year":"2025","journal-title":"RSC Med Chem"},{"key":"R33-20260810","first-page":"7957\u20138094","article-title":"Metallo-\u03b2-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design","volume":"121","year":"2021","journal-title":"Chem Rev"},{"key":"R34-20260810","first-page":"486\u201396","article-title":"In Vitro and In Vivo development of a \u03b2-Lactam-Metallo-\u03b2-Lactamase inhibitor: targeting carbapenem-resistant Enterobacterales","volume":"9","year":"2023","journal-title":"ACS Infect Dis"},{"key":"R35-20260810","article-title":"Metallo-\u03b2-Lactamases: structure, function, epidemiology, treatment options, and the development pipeline","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20260810","first-page":"142\u201350","article-title":"Combined dual \u03b2-lactams and diazabicyclooctane \u03b2-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro","volume":"42","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"R37-20260810","article-title":"Clinical efficacy, safety and pharmacokinetics of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: a systematic review","volume":"7","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"R38-20260810","first-page":"3001\u201306","article-title":"In Vitro and In Vivo activities of OP0595, a new diazabicyclooctane, against CTX-M-15-Positive escherichia coli and KPC-Positive Klebsiella pneumoniae","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20260810","first-page":"1815\u201324","article-title":"Role of Penicillin-Binding Protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A","volume":"187","year":"2005","journal-title":"J Bacteriol"},{"key":"R40-20260810","doi-asserted-by":"crossref","first-page":"pdb.prot087395","DOI":"10.1101\/pdb.prot087395","article-title":"Time-lapse imaging of cell death","volume":"2016","year":"2016","journal-title":"Cold Spring Harb Protoc"},{"key":"R41-20260810","first-page":"S416\u2013S416","article-title":"1359. Activity of Meropenem\/Nacubactam combination against gram-negative clinical isolates: ROSCO global surveillance 2017","volume":"5","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R42-20260810","doi-asserted-by":"crossref","first-page":"106330","DOI":"10.1016\/j.ijantimicag.2021.106330","article-title":"Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel \u03b2-lactamase inhibitor, nacubactam, against carbapenem-resistant and\/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model","volume":"57","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R43-20260810","first-page":"991\u201399","article-title":"Development of an optimized and practical pharmacokinetics\/pharmacodynamics analysis method for aztreonam\/nacubactam against carbapenemase-producing K. pneumoniae","volume":"78","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R44-20260810","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/antibiotics10101179","article-title":"In Vivo Pharmacodynamics of \u03b2-Lactams\/Nacubactam against Carbapenem-Resistant and\/or carbapenemase-producing enterobacter cloacae and klebsiella pneumoniae in murine pneumonia model","volume":"10","year":"2021","journal-title":"Antibiotics"},{"key":"R45-20260810","first-page":"547\u201353","article-title":"Simulated achievement rate of \u03b2-lactams\/nacubactam treatment in humans using instantaneous MIC-based PK\/PD analysis","volume":"80","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"R46-20260810","article-title":"Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone \u03b2-lactamase inhibitors against broad-spectrum AmpC \u03b2-lactamases","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R47-20260810","article-title":"Activity of meropenem\/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe","volume":"4","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"R48-20260810","first-page":"1696\u2013703","article-title":"WCK 5222 (cefepime\/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant \u03b2-lactamases","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R49-20260810","article-title":"In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"68","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R50-20260810","first-page":"1859\u201381","article-title":"\u03b2-lactamase inhibitors to restore the efficacy of antibiotics against superbugs","volume":"63","year":"2020","journal-title":"J Med Chem"},{"key":"R51-20260810","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/antibiotics14060587","article-title":"Challenges of carbapenem-resistant enterobacteriaceae in the development of new \u03b2-lactamase inhibitors and antibiotics","volume":"14","year":"2025","journal-title":"Antibiotics"},{"key":"R52-20260810","article-title":"Phenotypic profile and molecular mechanism of resistance in carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates from Brazilian hospitals: implications for the introduction of imipenem-relebactam","volume":"16","year":"2025","journal-title":"Front Microbiol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:00:45Z","timestamp":1786359645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005022","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2025-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}